Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are broadly supported by the provided label excerpts (e.g., LDL reduction, mechanism of HMG-CoA reductase inhibition, rhabdomyolysis/myopathy risk, hepatic dysfunction/liver injury risk, and certain cardiovascular risk-reduction indications). However, multiple specific alcohol-related and alcohol-combination risk claims (liver failure/transplantation, increased rhabdomyolysis, bleeding/alcohol escalation, dizziness/lightheadedness leading to falls/accidents, and nausea/vomiting leading to dehydration/electrolytes) are not supported by the provided labeling excerpts, and the alcohol drink-limiting guidance appears unsupported.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to treat high cholesterol.
Label excerpt Section 1.2 states LIPITOR is indicated as an adjunct to diet to reduce elevated lipids (e.g., elevated total-C, LDL-C, TG) in primary hypercholesterolemia and mixed dyslipidemia.
Lipitor reduces the risk of heart disease.
Section 1.1 includes indications to reduce risk of myocardial infarction, stroke, revascularization procedures, and angina in specified populations; these are cardiovascular outcomes.
Lipitor works by inhibiting the production of cholesterol in the liver.
Section 12.1: LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase.
Lipitor lowers levels of low-density lipoprotein (LDL) cholesterol in the blood.
Section 1.2 states LIPITOR reduces total-C and LDL-C (and other lipid parameters).
Lipitor can cause muscle damage (rhabdomyolysis).
Section 5.1: rare cases of rhabdomyolysis with acute renal failure have been reported. Section 6.2 lists rhabdomyolysis in postmarketing experience.
Rhabdomyolysis can lead to kidney failure.
Section 5.1: rare cases of rhabdomyolysis with acute renal failure have been reported.
Unsupported Statements
Consuming alcohol while taking Lipitor can increase the risk of liver damage.
No alcohol-specific liver-damage risk statement is present in the provided label excerpts.
The combination of Lipitor and alcohol can increase the risk of liver failure.
No alcohol-combination liver failure statement is present in the provided label excerpts.
The combination of Lipitor and alcohol can increase the risk of liver transplantation.
No alcohol-combination liver transplantation statement is present in the provided label excerpts.
The combination of Lipitor and alcohol can increase the risk of rhabdomyolysis (muscle damage).
No alcohol-combination myopathy/rhabdomyolysis risk statement is present in the provided label excerpts.
Rhabdomyolysis can cause muscle weakness.
Rhabdomyolysis is mentioned, but muscle weakness as a specific symptom is not supported by the provided excerpts.
Rhabdomyolysis can cause muscle pain.
Myalgia is listed as an adverse reaction, but muscle pain specifically attributed to rhabdomyolysis is not supported by the provided excerpts.
Lipitor can increase the risk of bleeding, particularly in the gastrointestinal tract.
No GI bleeding or bleeding risk statement is present in the provided label excerpts.
The combination of Lipitor and alcohol can further increase the risk of bleeding.
No alcohol-combination bleeding statement is present in the provided label excerpts.
Consuming too much alcohol while taking Lipitor can cause nausea and vomiting.
No alcohol-dose-related nausea/vomiting statement is present in the provided label excerpts.
Nausea and vomiting can lead to dehydration.
Causal statements (dehydration from nausea/vomiting) are not supported by the provided label excerpts.
Nausea and vomiting can lead to electrolyte imbalances.
Causal statements (electrolyte imbalances from nausea/vomiting) are not supported by the provided label excerpts.
The increased risk of liver damage and muscle damage from alcohol plus Lipitor can cause dizziness and lightheadedness.
No alcohol-combination liver/muscle risk leading to dizziness/lightheadedness is supported by the provided label excerpts.
Dizziness and lightheadedness can increase the risk of falls.
No label support provided for falls risk based on dizziness/lightheadedness.
Dizziness and lightheadedness can increase the risk of accidents.
No label support provided for accidents risk based on dizziness/lightheadedness.
The combination of Lipitor and alcohol can cause abdominal pain.
No alcohol-combination abdominal pain statement is present in the provided label excerpts.
The response states that the recommended guideline is to avoid consuming alcohol while taking Lipitor.
No alcohol avoidance guideline is present in the provided label excerpts.
If you consume alcohol while taking Lipitor, the response recommends limiting intake to no more than one drink per day for women.
No drink-per-day limitation guidance for alcohol is present in the provided label excerpts.
If you consume alcohol while taking Lipitor, the response recommends limiting intake to no more than two drinks per day for men.
No drink-per-day limitation guidance for alcohol is present in the provided label excerpts.
The response states that doctors may not prescribe Lipitor for patients who drink alcohol regularly.
No such prescribing restriction based on regular alcohol use is present in the provided label excerpts.
Contradictions
Low
AI Statement
Lipitor is contraindicated in patients with muscle damage.
Label Reference
Section 4 provides contraindications for active liver disease (including unexplained persistent elevations in hepatic transaminase levels), hypersensitivity, pregnancy, and nursing mothers; no contraindication for 'muscle damage' is shown in the provided excerpts.
Low
AI Statement
Lipitor is contraindicated in patients with liver damage.
Label Reference
The provided contraindication is 'active liver disease' (Section 4.1), not a general 'liver damage' contraindication in the excerpts.
Important Omissions
For the safety-related claims, label-based cautions are not reflected in the response set (e.g., 'liver function tests prior to and at 12 weeks' and 'temporarily withheld or discontinued' guidance for muscle issues, and interaction-driven myopathy risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several specific alcohol-related and alcohol-combination risk and dose-limiting recommendations are unsupported by the provided label excerpts, and the contraindication statements regarding 'muscle damage' and generalized 'liver damage' are not supported as written. While some core statin safety signals (rhabdomyolysis, liver dysfunction) are present, the unsupported guidance could mislead decision-making about alcohol use and contraindications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported alcohol-specific and causal chain claims, plus inaccurate/overbroad contraindication wording not shown in the provided label excerpts.
Suggested Improvement
Remove or rewrite alcohol-combination and alcohol-dose limitation claims unless supported by label text; align contraindications specifically to 'active liver disease' and the listed contraindication categories shown; restrict safety statements to label-supported risks (e.g., rhabdomyolysis/myopathy risk and liver dysfunction monitoring) without unsupported mechanisms or outcomes.